stella
beta
A Phase I First-in-Human Study of GenSci128 in Patients With Solid Tumors Harboring a TP53 Y220C Mutation — Stella
Recruiting
Back to Solid Tumors Harboring a TP53 Y220C Mutation trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
Trial locations
(1 site)
China
Zhongshan Hospital ,Fudan University, Shanghai, Shanghai Municipality
View full record on ClinicalTrials.gov